pharma

YOU MIGHT BE INTERESTED IN

The Global Vaccines Market 2008-2023
The key growth driver for vaccines is their cost-effectiveness in combating disease. This situation will encourage greater use of vaccines by governments and private healthcare providers. New disease targets that could be mitigated through vaccination, including high profile (and potentially profitable) targets such as cancer.
...more details

CONFERENCE

...see all

Vaccine Research & Development 2009

Moving from technology to manufacturing and production

7th - 8th December 2009, BSG House, London, UK

Download brochure Products

Background Info
Day 1
Day 2
Partners
Past Papers

Media Partners

Background Info

Key Speakers
• Eric Claessens, Director of Bulk Technologies, GlaxoSmithKline Biologicals
• Mark A. Fletcher, Senior Director, International Scientific & Clinical Affairs, Pfizer
• Guido Grandi, Senior Project Leader, Novartis Vaccines and Diagnostics
• Jon H. Heinrichs, Senior Research Fellow, Vaccine Basic Research, Merck Research Laboratories
• James Merson, Vice President and Chief Scientific Officer, Vaccines Research Unit, Pfizer
• Alexander von Gabain, Chief Scientific Officer, Intercell
• Barry Buckland, Chief Executive Officer, BiologicB
• Andrew Baum, Managing Director Equity Research, Morgan Stanley
• Hélène Pora, Director, Vaccine Application Development, Pall Life Sciences
• Raf Lemmens, Global Fast Trak Leader, GE Healthcare Life Sciences
• Othmar Engelhardt, Principal Scientist, National Institute for Biological Standards and Control
• Jacqui Shea, General Manager, Oxford-Emergent Tuberculosis Consortium
• Pete Gagnon, Chief Scientific Officer, Validated Biosystems
• Bernd Eisele, Chief Executive Officer, Vakzine Projekt Management
• John Savopulos, Director, VacZine Analytics
• David Kirke, Associate Director, ERA Consulting

We stand poised for the second golden era of vaccines, born of new advances in fields from recombinant molecular biology, to mass spectrometry, and bioinformatics¹. Allied with new advances in formulation and process development, the global market will see growth of over 300% between 2009and 2023^1,2.

With more targets, more investment and more opportunity than ever, vaccinology has become one of the most dynamic fields in biomedicine today. Progress in reverse vaccinology, immuno-informatics and disposable technologies are revolutionising R&D for infectious disease, paediatric and cancer therapies.

And, as demonstrated by Prevnar, Infanrix and Gardasil, the blockbuster model, far from being obsolete, is alive and kicking in an arena historically characterised by low margins.

The rise of developing economies and new markets in the Asia-Pacific regions are augmenting the financial promise shown by new paediatric and adult therapies, pointing to a bright future ahead.

By attending Visiongain’s Vaccine Research & Development conference, you will benefit from distilled, market-focussed intelligence on the future for this exciting sector, from outstanding speakers in key areas including:
• Economic analysis of future trends including opportunities, drivers and challenges
• The R&D pipeline: future impact of new technologies
• How reverse vaccinology produced the H1N1 vaccine
• Progress towards a paediatric and adult 13 valent pneumococcal vaccine
• Surface proteome analysis as a fast-track for development of a GAS vaccine
• Clinical results for a new subunit booster vaccine for tuberculosis
• Development of a recombinant booster for prostate cancer
• New needle-free delivery methods
• Implementation of disposable technology in manufacturing
• Revisiting old tools in vaccine development
• MDCK cell-based based production methods and scale-up design considerations in bio-pharmaceutical manufacturing
• Purification of virus particles and DNA plasmids with monoliths
• The role of neutralising and monoclonal antibodies
• Collaborative partnering with lesser-developed countries
• BRIC countries in vaccine production

¹ Poland, G.A. (2007). Pharmacology, Vaccinomics, and the Second Golden Age of Vaccinology. Clinical Pharmacology & Therapeutics, 82 (6), pp. 623-626.
² Visiongain (2008). The Global Vaccines Market 2008-2023.

Day 1

Day One, Monday 7th December 2009

09:30 Registration and refreshments

10:00 Opening address from the chair

James Merson
Vice President and Chief Scientific Officer, Vaccines Research Unit
Pfizer

10:10 The global vaccine technology market: opportunities, drivers and challenges
• Drivers impacting industry investment in vaccines
• Factors increasing demand for advanced vaccine analytics
• Prospects for growth and strategic directions

Andrew Baum
Managing Director, Equity Research
Morgan Stanley

10:50 The vaccine R&D pipeline: future impact of new technologies
• Dynamics of vaccine market
• R&D pipeline – focus on emerging technologies
• Which companies are pursuing new vaccine technologies?
• Opportunities and challenges of new vaccine technologies

John Savopulos
Director
VacZine Analytics

11:30 Morning refreshments

11:50 Genomics in the discovery and design of novel vaccines for bacterial pathogens
• Use of genomics to identify vaccine targets for microbial pathogens
• Characterization of vaccine antigens using genomic tools
• Validation of vaccine targets in relevant model systems

Jon H. Heinrichs
Senior Research Fellow, Vaccine Basic Research
Merck Research Laboratories

12:30 Case study: Surface proteome analysis as a fast-track to vaccine discovery
• Stripping away cell-surface proteins
• Mass-spectrometry and in silico surfome analysis
• Identification and validation of new targets for group A Streptococcus

Guido Grandi
Senior Project Leader
Novartis Vaccines and Diagnostics

13:10 Networking lunch

14:30 Progress towards a paediatric and adult 13 valent pneumococcal vaccine
• Success of pneumococcal conjugate vaccine
• Changing epidemiology of pneumococcal infection
• Immunological considerations and correlates
• Development of new pneumococcal vaccines

Mark A. Fletcher
Senior Director, International Scientific & Clinical Affairs
Pfizer

15:10 Vaccine purification with monoliths
• How monoliths relate to porous particle and membrane-based media
• How monoliths support 10-100 times greater productivity than traditional media
• Examples from purification of virus particles and DNA plasmids

Pete Gagnon
Chief Scientific Officer
Validated Biosystems

15:50 Afternoon refreshments

16:10 Cell-based influenza vaccine process development and analysis: lessons learnt
• Analytical challenges in process development
• Approaches to purifying multiple strains
• Considerations on the use of single-use vs. conventional purification technology

Robert Magnusson
Project Manager
GE Healthcare Life Sciences

16:50 Implementation of disposable technology in vaccine manufacturing
• Where disposable technology is applicable in vaccine processing
• Why is it attractive in vaccine manufacturing
• Some examples of application including timelines
• Validation aspects
• Conclusion with references to the impact on the environment

Hélène Pora
Director, Vaccine Application Development
Pall Life Sciences

17:30 Closing remarks from the chair

17:40 Networking drinks

Day 2

Day Two, Tuesday 8th December 2009

09:30 Registration and refreshments

10:00 Opening address from the Co-Chairs

Barry Buckland
Chief Executive Officer, BiologicB
And Strategic Technical Advisor, MSD and Wellcome Trust Hilleman Laboratories

Bernd Eisele
Chief Executive Officer
Vakzine Projekt Management

10:10 The Hilleman laboratory; an innovative approach to improve universal access to vaccines
• Development of new vaccines for neglected diseases
• Technology enhancements to improve access to both existing and novel vaccines
• Partnerships for improved technology transfer
• Hilleman Laboratory is a Joint Venture between Merck & Co.Inc and The Wellcome Trust

Barry Buckland
Chief Executive Officer, BiologicB
And Strategic Technical Advisor, MSD and Wellcome Trust Hilleman Laboratories

10:50 Micro-scale models and their application for rapid vaccine development.
• Robust and accurate models are needed to reduce time in development
• Micro-scale models are capable of using high throughput platforms and generate quantitative data
• This data can be used to accurately scale up to commercial process.

Tarit Mukhopadhyay
Lecturer in Vaccine Bioprocess Development
University College London

11:30 Morning refreshments

11:50 Emergency preparedness and response: where the public sector can play a role in developing interventions such as vaccines
• What role can vaccines play in preparedness and response?
• Reality of developing and manufacturing new vaccines to meet the challenge
• HPA translational research model
• A strategic vaccine concept

Bassam Hallis
Project Manager
Health Protection Agency

12:30 Case study: Developing the first vaccine virus for pandemic H1N1
• Reverse vaccinology for H1N1
• Isolation, testing and validation
• Production and distribution

Othmar Engelhardt
Principal Scientist
National Institute for Biological Standards and Control

13:10 Networking lunch

14:30 From a needle-free ETEC vaccine to a vaccine enhancement patch
• Epidermal skin, an optimal site for vaccine delivery
• A patch delivering ETEC vaccine based on LT toxin
• LT toxin functions as a vaccine enhancement tool when delivered via the skin

Alexander von Gabain
Chief Scientific Officer
Intercell

15:10 Case study: MVA85A- a new subunit booster vaccine for tuberculosis

Jacqui Shea
General Manager
Oxford-Emergent Tuberculosis Consortium

15:50 Afternoon refreshments

16:10 Development of an rBCG adjuvanted allogeneic vaccine against prostate cancer
• Development of a GM live vaccine (VPM1002) against tuberculosis: results from phase I trials
• Development of an allogeneic therapeutic vaccine (VPM4001) against prostate cancer: phase I/II results
• A boosting/adjuvant strategy: VPM4001 + VPM1002 to increase the Th1 immune response against prostate cancer

Bernd Eisele
Chief Executive Officer
Vakzine Projekt Management

16:50 Current regulatory concerns regarding long-term safety of vaccines
• Current safety challenges
• Balancing purity of the antigen and adjuvant with adequate antigenicity
• Models for pre-clinical testing, and clinical trials demonstrating adequate safety

David Kirke
Associate Director
ERA Consulting

17:30 Chair’s closing remarks

17:40 End of conference

Partners

Media Partners:

PharmiWeb.com
PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Supported by most of the leading pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features, events listings and international jobs to industry professionals across Europe and the US. For further information please email: corporate@pharmiweb.com

BIOTECHNOLOGY EUROPE
BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world’s biotech and pharma information and market to make it universally accessible and useful for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public relations, publication and marketing solutions. One of the main goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities. For further information please visit www.biotechnology-europe.com

Future Pharmaceuticals
Future Pharmaceuticals has forged powerful relationships with key industry leaders to provide a platform for successful brand recognition, and for senior decision-makers to have the means to procure and plan implementation strategies based on the topics covered. Positioned to be an authoritative resource within top pharma companies as well as small, specialty, and biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into a highly targeted and responsive audience, bridging the gap between the industries' top issues and the solutions top-tier vendors can provide. For further information, please visit www.futurepharmaus.com

InPharm
InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus. For further information please visit: www.In-Pharm.com

Pharma Connections Worldwide
Pharma Connections Worldwide® is the leading professional business networking website focused in the Pharmaceutical, Biotechnology and Life Sciences research industry. Our goal is to provide a conduit for delivery of premiere content coupled with the right clientele in order to facilitate business development opportunities among industry professionals responsible for making key decisions in a global marketplace. For further information please visit www.pharmaconnections.com

Enquiries

If you would like more information on the range of sponsorship or exhibition possibilities for visiongain's Vaccine Research & Development conference, please contact us:
Sandra Clout PhD, +44 (0)20 7549 9969
sandra.clout@visiongainglobal.com

Past Papers

Speaker presentations are free to delegates. If you are unable to attend the event, the presentations are published two weeks after the event and are available to purchase.

Buy Now